Direct bone effects of calcimimetics in chronic kidney disease? | Zendy

Sandro Mazzaferro | Zendy; Marzia Pasquali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Direct bone effects of calcimimetics in chronic kidney disease?

Author(s) -

Sandro Mazzaferro,

Marzia Pasquali

Publication year - 2019

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1016/j.kint.2019.01.045

Subject(s) - parathyroid hormone , secondary hyperparathyroidism , endocrinology , calcimimetic , medicine , calcium sensing receptor , hyperparathyroidism , bone remodeling , cinacalcet , primary hyperparathyroidism , chemistry , calcium

Calcimimetics are widely used in patients on dialysis to treat secondary hyperparathyroidism. Our current view is that bone effects are only indirect through parathyroid hormone suppression. However, because bone cells express the calcium-sensing receptor, direct calcium-sensing receptor-mediated effects are also possible. New experimental data demonstrate direct anabolic bone actions of calcimimetics, independent of parathyroid hormone suppression. Because these effects could be clinically useful, further studies are necessary to confirm the validity of this observation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research